13:26:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2023
2023-11-13 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 Årsstämma 2023
2023-03-24 Extra Bolagsstämma 2022
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2021-11-08 08:30:00

Covid-19 test sales moving to Egoo platform

FINANCIAL SUMMARY - THIRD QUARTER 2021
  • Revenue in the period amounted to kSEK 5,871 (5,062). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -12,229 (-5,043), and net loss kSEK -14,998 (-2,757).
  • The total cash flow in the third quarter amounted to kSEK -25,580 (-11,714).
  • Earnings per share before/after dilution for the third quarter amounted to SEK -1.13 (-0.25), calculated on weighted average number of shares in the period.
 FINANCIAL SUMMARY - JANUARY -SEPTEMBER 2021
  • Revenue in the period amounted to kSEK 27,529 (11,628). Revenue regards sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -23,533 (-12,921), and net loss kSEK -33,533 (-12,598).
  • The total cash flow in the nine months period amounted to kSEK 61,907 (16,266).
  • The positive cash flow is related to the new issue of shares and exercise of warrants (TO1).
  • Shareholders equity as of 30 September amounted to kSEK 178,490 (99,299).
  • Earnings per share before/after dilution for the nine months amounted to SEK -2.70 (-1.22), calculated on weighted average number of shares in the period.
SIGNIFICANT EVENTS - THIRD QUARTER 2021
  • In July Qlife submitted a scientific study of the company's COVID-19 test to Natures Scientific Reports for publication. The study demonstrates the potential of Qlife's mobile test platform Egoo.Health and COVID-19 tests that can deliver exactly the same clinical quality as laboratory tests in 30 minutes.
 
  • Niklas Marschall left the Board of Qlife Holding AB and Qlife ApS.
SIGNIFICANT EVENTS AFTER END OF THIRD QUARTER 2021
  • In accordance with the decision at Qlife Holding's Annual General assembly a Nomination committee has been convened. The Nomination committee consist of the following persons: Anita Otterheim Hjalmarsson, Sören Skjärbäk, Lars Bangsgaard and Mette Gross.
  • In November, the scientific study of the company's COVID-19 on the Egoo platform test was accepted for publication in Natures Scientific Reports. The complete study will be available shortly in Scientific Reports (

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-11-2021 08:30 CET.